Cited by 225Down syndrome and intellectual disability researchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 160 of the 163 references it cites were found in a registry or an index.

Neurological phenotypes for Down syndrome across the life span

Open access
Lott, Ira T.·2012·Progress in Brain Research

Abstract

This chapter reviews the neurological phenotype of Down syndrome (DS) in early development, childhood, and aging. Neuroanatomic abnormalities in DS are manifested as aberrations in gross brain structure as well as characteristic microdysgenetic changes. As the result of these morphological abnormalities, brain circuitry is impaired. While an intellectual disability is ubiquitous in DS, there is a wide range of variation in cognitive performance and a growing understanding between aberrant brain circuitry and the cognitive phenotype. Hypotonia is most marked at birth, affecting gait and ligamentous laxity. Seizures are bimodal in presentation with infantile spasms common in infancy and generalized seizures associated with cognitive decline observed in later years. While all individuals have the characteristic neuropathology of Alzheimer's disease (AD) by age 40 years, the prevalence of dementia is not universal. The tendency to develop AD is related, in part, to several genes on chromosome 21 that are overexpressed in DS. Intraneuronal accumulation of β-amyloid appears to trigger a cascade of neurodegeneration resulting in the neuropathological and clinical manifestations of dementia. Functional brain imaging has elucidated the temporal sequence of amyloid deposition and glucose metabolic rate in the development of dementia in DS. Mitochondrial abnormalities contribute to oxidative stress which is part of AD pathogenesis in DS as well as AD in the general population. A variety of medical comorbidities threaten cognitive performance including sleep apnea, abnormalities in thyroid metabolism, and behavioral disturbances. Mouse models for DS are providing a platform for the formulation of clinical trials with intervention targeted to synaptic plasticity, brain biochemistry, and morphological brain alterations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/b978-0-444-54299-1.00006-6

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People with Down syndrome often develop Alzheimer-like dementia at approximately 40 to 50 years of age.

    “One striking characteristic of people with DS is that at approximately 40–50 years of age, AD-like dementia often appears59,60.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [59]

    The Dementia section says that Alzheimer’s disease neuropathology is present in people with Down syndrome by age 40, and the Abstract says they have a tendency to develop dementia. But the paper distinguishes neuropathology from clinical dementia, whose prevalence it says is not universal; these passages do not establish that dementia often appears specifically at ages 40–50. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Both a dose effect from APP triplication and gene-environment interactions likely contribute to Alzheimer-like dementia in Down syndrome.

    “It is likely that both a dose effect of triplication of APP and gene-environment interactions play a role59,60.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [59]

    The Dementia section links increased APP gene dosage in Down syndrome to early β-amyloid deposition, supporting the APP-dose part of the claim. The introductory section says the neurological phenotype reflects genetic expression and environmental influences, but our copy does not specifically link gene–environment interactions to Alzheimer-like dementia. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Down syndrome phenotypes result from full or partial triplication of chromosome 21.

    “The varied phenotypes of DS result from full or partial triplication of chromosome 21, the most common human chromosomal disorder59.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [59]

    The Dementia section links Down syndrome to trisomy 21 and overexpression of a chromosome 21 gene, while the Neuroanatomic abnormalities section discusses effects of an extra chromosome 21 on development. These passages support a chromosome 21 basis for Down syndrome phenotypes, but the copy does not establish that partial triplication of chromosome 21 produces the varied human phenotypes; its reference to partial trisomy concerns mice. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Other chromosome 21-encoded proteins may be involved in Down syndrome, including Cu/Zn-superoxide dismutase and Bach1.

    “Other proteins encoded on chromosome 21 may be involved59, such as Cu/Zn-superoxide dismutase (which is an important antioxidant enzyme normally, but can be deleterious if excess is present8) and Bach1 (transcriptional inhibitor of heme oxygenase-1, HO-1).”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [59]

    The Dementia section (page not available in our copy) names superoxide dismutase among chromosome 21 genes implicated in Alzheimer’s disease pathology in Down syndrome. It does not mention Bach1 or describe its proposed role, so that example is unsupported by this source. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Flagged first, then by citations

3 of the 163 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Metadata

Authors
Lott, I. T.
Affiliations
University of California, Irvine (US)
Corresponding author
Lott, Ira T.
Venue
Progress in Brain Research
Publisher
Elsevier
Published
2012
Volume
197
Pages
101-121
ISSN
0079-6123 (ISSN-L)
OpenAlex
W1829879414
Cited by
225
References
163
Citations by year
2026: 6 · 2025: 18 · 2024: 13 · 2023: 14 · 2022: 19 · 2021: 22 · 2020: 21 · 2019: 14 · 2018: 15 · 2017: 18 · 2016: 13 · 2015: 17 · 2014: 22 · 2013: 10 · 2012: 3
FWCI
38.75
Type
book chapter
Language
en
Open access
Locations
  • Progress in brain research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (AG 21912, P50AG016573, R01AG021912)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065160, HD 37427, HD-065160, R01HD037427)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Down syndrome, neurological phenotype, intellectual disability, brain circuits, hypotonia, infantile spasms, seizures, Alzheimer's disease, dementia, chromosome 21 genes, amyloid-beta, neurodegeneration, glucose metabolism, mitochondrial dysfunction, oxidative stress, sleep apnea, thyroid metabolism, behavioral problems, mouse model, synaptic plasticity, aging
MeSH terms
Age Factors, Aging, Brain, Cognition Disorders, Down Syndrome, Humans, Muscle Hypotonia, Nervous System Diseases, Phenotype, Amyloid beta-Peptides, Mitochondrial Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review